Cysteine Catabolism and the Serine Biosynthesis Pathway Support Pyruvate Production During Pyruvate Kinase Knockdown in Pancreatic Cancer Cells

Overview

Journal Cancer Metab

Publisher Biomed Central

Specialty Oncology

Date 2020 Jan 2

PMID 31893043

Citations 26

Authors

Lei Yu

Shao Thing Teoh

Elliot Ensink

Martin P Ogrodzinski

Che Yang

Ana I Vazquez

Sophia Y Lunt

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with limited treatment options. Pyruvate kinase, especially the M2 isoform (PKM2), is highly expressed in PDAC cells, but its role in pancreatic cancer remains controversial. To investigate the role of pyruvate kinase in pancreatic cancer, we knocked down PKM2 individually as well as both PKM1 and PKM2 concurrently (PKM1/2) in cell lines derived from a pancreatic mouse model.

Methods: We used liquid chromatography tandem mass spectrometry (LC-MS/MS) to determine metabolic profiles of wildtype and PKM1/2 knockdown PDAC cells. We further used stable isotope-labeled metabolic precursors and LC-MS/MS to determine metabolic pathways upregulated in PKM1/2 knockdown cells. We then targeted metabolic pathways upregulated in PKM1/2 knockdown cells using CRISPR/Cas9 gene editing technology.

Results: PDAC cells are able to proliferate and continue to produce pyruvate despite PKM1/2 knockdown. The serine biosynthesis pathway partially contributed to pyruvate production during PKM1/2 knockdown: knockout of phosphoglycerate dehydrogenase in this pathway decreased pyruvate production from glucose. In addition, cysteine catabolism generated ~ 20% of intracellular pyruvate in PDAC cells. Other potential sources of pyruvate include the sialic acid pathway and catabolism of glutamine, serine, tryptophan, and threonine. However, these sources did not provide significant levels of pyruvate in PKM1/2 knockdown cells.

Conclusion: PKM1/2 knockdown does not impact the proliferation of pancreatic cancer cells. The serine biosynthesis pathway supports conversion of glucose to pyruvate during pyruvate kinase knockdown. However, direct conversion of serine to pyruvate was not observed during PKM1/2 knockdown. Investigating several alternative sources of pyruvate identified cysteine catabolism for pyruvate production during PKM1/2 knockdown. Surprisingly, we find that a large percentage of intracellular pyruvate comes from cysteine. Our results highlight the ability of PDAC cells to adaptively rewire their metabolic pathways during knockdown of a key metabolic enzyme.

Citing Articles

The Current Applications of Metabolomics in Understanding Endometriosis: A Systematic Review.

Collie B, Troisi J, Lombardi M, Symes S, Richards S Metabolites. 2025; 15(1).

PMID: 39852392 PMC: 11767062. DOI: 10.3390/metabo15010050.

PHGDH: a novel therapeutic target in cancer.

Lee C, Hwang Y, Kim M, Park Y, Kim H, Fang S Exp Mol Med. 2024; 56(7):1513-1522.

PMID: 38945960 PMC: 11297271. DOI: 10.1038/s12276-024-01268-1.

O-GlcNAc signaling increases neuron regeneration through one-carbon metabolism in .

Yadav D, Chang A, Grooms N, Chung S, Gabel C Elife. 2024; 13.

PMID: 38334260 PMC: 10857789. DOI: 10.7554/eLife.86478.

Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review.

Perazzoli G, Garcia-Valdeavero O, Pena M, Prados J, Melguizo C, Jimenez-Luna C Metabolites. 2023; 13(7).

PMID: 37512579 PMC: 10384620. DOI: 10.3390/metabo13070872.

PKM2 deficiency exacerbates gram-negative sepsis-induced cardiomyopathy via disrupting cardiac calcium homeostasis.

Ni L, Lin B, Shen M, Li C, Hu L, Fu F Cell Death Discov. 2022; 8(1):496.

PMID: 36564378 PMC: 9789059. DOI: 10.1038/s41420-022-01287-9.

References

Sato T, Morita M, Nomura M, Tanuma N . Revisiting glucose metabolism in cancer: lessons from a PKM knock-in model. Mol Cell Oncol. 2018; 5(4):e1472054. PMC: 6149909. DOI: 10.1080/23723556.2018.1472054. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Christofk H, Vander Heiden M, Harris M, Ramanathan A, Gerszten R, Wei R . The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008; 452(7184):230-3. DOI: 10.1038/nature06734. View

Morita M, Sato T, Nomura M, Sakamoto Y, Inoue Y, Tanaka R . PKM1 Confers Metabolic Advantages and Promotes Cell-Autonomous Tumor Cell Growth. Cancer Cell. 2018; 33(3):355-367.e7. DOI: 10.1016/j.ccell.2018.02.004. View

Bandara I, Baltatzis M, Sanyal S, Siriwardena A . Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer. World J Surg Oncol. 2018; 16(1):56. PMC: 5853155. DOI: 10.1186/s12957-018-1360-3. View

Yoshino H, Nohata N, Miyamoto K, Yonemori M, Sakaguchi T, Sugita S . PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma. Cancer Res. 2017; 77(22):6321-6329. PMC: 5893502. DOI: 10.1158/0008-5472.CAN-17-1589. View

Yamada T, Komoto J, Takata Y, Ogawa H, Pitot H, Takusagawa F . Crystal structure of serine dehydratase from rat liver. Biochemistry. 2003; 42(44):12854-65. DOI: 10.1021/bi035324p. View

Jurica M, Mesecar A, Heath P, Shi W, Nowak T, Stoddard B . The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure. 1998; 6(2):195-210. DOI: 10.1016/s0969-2126(98)00021-5. View

Conroy T, Bachet J, Ayav A, Huguet F, Lambert A, Caramella C . Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016; 57:10-22. DOI: 10.1016/j.ejca.2015.12.026. View

10.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

11.

Ogawa H, Nagano H, Konno M, Eguchi H, Koseki J, Kawamoto K . The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer. Mol Clin Oncol. 2015; 3(3):563-571. PMC: 4471544. DOI: 10.3892/mco.2015.490. View

12.

Dayton T, Jacks T, Vander Heiden M . PKM2, cancer metabolism, and the road ahead. EMBO Rep. 2016; 17(12):1721-1730. PMC: 5283597. DOI: 10.15252/embr.201643300. View

13.

Zhang B, Zheng A, Hydbring P, Ambroise G, Ouchida A, Goiny M . PHGDH Defines a Metabolic Subtype in Lung Adenocarcinomas with Poor Prognosis. Cell Rep. 2017; 19(11):2289-2303. DOI: 10.1016/j.celrep.2017.05.067. View

14.

Cortes-Cros M, Hemmerlin C, Ferretti S, Zhang J, Gounarides J, Yin H . M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc Natl Acad Sci U S A. 2012; 110(2):489-94. PMC: 3545759. DOI: 10.1073/pnas.1212780110. View

15.

Takenaka M, Yamada K, Lu T, Kang R, Tanaka T, Noguchi T . Alternative splicing of the pyruvate kinase M gene in a minigene system. Eur J Biochem. 1996; 235(1-2):366-71. DOI: 10.1111/j.1432-1033.1996.00366.x. View

16.

Melamud E, Vastag L, Rabinowitz J . Metabolomic analysis and visualization engine for LC-MS data. Anal Chem. 2010; 82(23):9818-26. PMC: 5748896. DOI: 10.1021/ac1021166. View

17.

Lau A, Israelsen W, Roper J, Sinnamon M, Georgeon L, Dayton T . PKM2 is not required for colon cancer initiated by APC loss. Cancer Metab. 2017; 5:10. PMC: 5707917. DOI: 10.1186/s40170-017-0172-1. View

18.

Wang Y, Israelsen W, Lee D, Yu V, Jeanson N, Clish C . Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell. 2014; 158(6):1309-1323. PMC: 4197056. DOI: 10.1016/j.cell.2014.07.048. View

19.

Osterman J, FRITZ P . Pyruvate kinase isozymes: a comparative study in tissues of various mammalian species. Comp Biochem Physiol B. 1973; 44(4):1077-85. DOI: 10.1016/0305-0491(73)90261-7. View

20.

Falasca M, Kim M, Casari I . Pancreatic cancer: Current research and future directions. Biochim Biophys Acta. 2016; 1865(2):123-32. DOI: 10.1016/j.bbcan.2016.01.001. View